Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: A systematic review and meta-analysis

EuroIntervention

Volumn 6, Issue 4, 2010, Pages 527-536

  Testa, Luca ^a   Agostoni, Pierfrancesco ^b   Vermeersch, Paul ^c   Biondi Zoccai, Giuseppe ^d   Van Gaal, William ^e   Bhindi, Ravinay ^f   Brilakis, Emmanouil ^g   Latini, Roberto A ^a   Laudisa, Maria Luisa ^a   Pizzocri, Samuele ^a   Lanotte, Stefania ^a   Brambilla, Nedy ^a   Banning, Adrian ^h   Bedogni, Francesco ^a  

^a Department of Interventional Cardiology   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Antwerp Cardiovascular Institute   (Belgium)

^d UNIVERSITY OF TURIN   (Italy)

^e NORTHERN HOSPITAL   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Bare metal stent; Complex lesions; Drug eluting stent

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; BARE METAL STENT; CLINICAL EFFECTIVENESS; COMPLICATION; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; SYSTEMATIC REVIEW; VEIN GRAFT DISEASE; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; FOLLOW UP; GRAFT OCCLUSION; INSTRUMENTATION; SAPHENOUS VEIN; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; SAPHENOUS VEIN; STENTS;

EID: 79951984293     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJ30V6I4A87     Document Type: Review

References (47)

1. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery) Developed in Collaboration With the American Association for Thoracic Surgery and the Society of Thoracic Surgeons. Available at www.cardiosource.com (last access 11th June 2008).
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616-26 (Pubitemid 26288642)
3. Weintraub WS, Jones EL, Morris DC, King SB 3rd, Guyton RA, Craver JM. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation. 1997;95:868-77. (Pubitemid 27091527)
4. Baim D. Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. J Am Coll Cardiol 2003;42:1370-1372. (Pubitemid 37267274)
5. Agostoni P, Vermeersch P. Percutaneous treatment of saphenous vein graft. Cardiology Intern. 2008 (Summer) 45-50.
6. Smith SC, Jr., Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:e1-121.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23. (Pubitemid 37186209)
8. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423-31. (Pubitemid 44895571)
9. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G; DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-7. (Pubitemid 47039289)
10. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bisset JK, Sachdeva R, Voudris VV, Karyiofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomised controlled trial of a Pclitaxel eluting stent versus similar bare metal stent in saphenous vein graft lesions. The SOS trial. J Am Coll Cardiol. 2009;53:919-28.
11. Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, Handke M, Osswald S, Buser PT, Pfisterer ME; Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. BASKET Investigators. Cardiology. 2009;112:49-55. Epub 2008 Jun 26.
12. Biondi Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005;34:224-5. (Pubitemid 40347400)
13. Review Manager 4.2.2. Available from The Cochrane Collaboration at http://www.cochrane.org/***.
14. Higgins JPT, Green S. Cochrane Reviewers' Handbook 5.0.0. Available at http://www.cochrane-handbook.org. Last access (11th July 2008)
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
17. Biondi-Zoccai GGL, Testa L, Agostoni P. A practical algorithm for systematic reviews in cardiovascular medicine. Ital Heart J 2004; 5:486-7.
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12.
19. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Colombo A. Treatment of Saphenous Vein Graft Lesions With Drug-Eluting Stents. Immediate and Midterm Outcome. J Am Coll Cardiol 2005;45:989-94. (Pubitemid 40432427)
20. Hoffmann R, Pohl T, Köster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart. 2007;93:331-4. (Pubitemid 46579523)
21. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66:507-11. (Pubitemid 41779016)
22. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97:34-7. (Pubitemid 41828119)
23. Wöhrle J, T. Nusser, H.A. Kestler, M. Kochs, V. Hombach. Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol. 2007;96:70-76. (Pubitemid 46233208)
24. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, Resnic F, Yakubov S, Callahan K, Borgman M, Cohen SA. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol. 2007;19:404-9. (Pubitemid 47509462)
25. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, Piovaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Marzocchi A. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol. 2008;101:947-52.
26. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, Wong SC. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol. 2007;20:458-65. (Pubitemid 350179467)
27. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, Mehta JL, and Sachdeva R. Percutaneous Intervention on the Saphenous Vein Bypass Grafts-Long-Term Outcomes. Catheter Cardio Inte. 2008;71:58-61. (Pubitemid 351158347)
28. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, Mattai W. Lack of Clinical Long-Term Benefit With the Use of a Drug Eluting Stent Compared to Use of a Bare Metal Stent in Saphenous Vein Grafts. Catheter Cardio Inte. 2008;72:13-20. (Pubitemid 352008974)
29. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, Liu J, Loeb H, Lewis BE. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv. 2008;71:886-93. (Pubitemid 351951305)
30. Applegate RJ, Sacrinty M, Kutcher M, Santos R, Gandhi S, Little W. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. Catheter Cardiovasc Interv. 2008;72:7-12. (Pubitemid 352013502)
31. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Kornowski R. Beneficial 2-years results of drug eluting stents in saphenous vein graft lesions. EuroIntervention. 2008;4:108-114.
32. van Twisk PT, Daemen J, Kukreja N, can Domburg RT, Serruys P. Four-year safety and efficacy of the unrestricted use of sirolimus and paclitaxel stents in coronary artery bypass grafts. EuroIntervention 2008;4:311-317.
33. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, Pinto Slottow TL, Smith K, Torguson R, Xue Z, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R. Drug eluting stent versus bare metal stent for narrowing in saphenous vein graft. Am J Cardiol 2008;102:530-534.
34. Webb JG, Carere RG, Virmani R, Baim D, Teirstein PS, Whitlow P, McQueen C, Kolodgie FD, Buller E, Dodek A, Mancini GB, Oesterle S. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol. 1999;34:468-75.
35. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol. 1994;9:641-9. (Pubitemid 24341152)
36. Depre C, Havaux X, Wijns W. Pathology of restenosis in saphenous bypass grafts after long-term stent implantation. Am J Clin Pathol. 1998;110:378-84. (Pubitemid 28406997)
37. van Beusekom HM, van der Giessen WJ, van Suylen R, Bos E, Bosman FT, Serruys PW. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol. 1993;21:45-54. (Pubitemid 23031294)
38. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52. (Pubitemid 29035956)
39. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23. (Pubitemid 37186209)
40. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-7. (Pubitemid 38544483)
41. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806. (Pubitemid 44268230)
42. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-55. (Pubitemid 46648381)
43. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. (Pubitemid 46376800)
44. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78. (Pubitemid 46281313)
45. Ellis SG. "Crying fire in a theatre" or a "Confirmatory sighting"? JACC 2007;50:268-9.
46. http://www.clinicaltrials.gov/ct2/show/NCT00611910?term= isar+cabg&rank=1
47. http://www.clinicaltrials.gov/ct2/show/NCT00595647?term=basket&rank=6